Mutational profile of hereditary breast and ovarian cancer – Establishing genetic testing guidelines in a developing country

Prat, 2005, Hereditary ovarian cancer, Hum Pathol, 36, 861, 10.1016/j.humpath.2005.06.006 Newman, 1988, Inheritance of human breast cancer: Evidence for autosomal dominant transmission in high-risk families, Proc Natl Acad Sci U S A, 85, 3044, 10.1073/pnas.85.9.3044 Finch, 2014, Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation, J Clin Oncol, 32, 1547, 10.1200/JCO.2013.53.2820 Caulfield, 2019, Olaparib: a novel therapy for metastatic breast cancer in patients with a BRCA1/2 mutation, J Adv Pract Oncol, 10, 167 Alsop, 2012, BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group, J Clin Oncol, 30, 2654, 10.1200/JCO.2011.39.8545 Ledermann, 2014, Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial, Lancet Oncol, 15, 852, 10.1016/S1470-2045(14)70228-1 Willoughby, 2019, Genetic testing to guide risk-stratified screens for breast cancer, J Pers Med, 9, 10.3390/jpm9010015 Beitsch, 2019, Underdiagnosis of hereditary breast cancer: Are genetic testing guidelines a tool or an obstacle?, J Clin Oncol, 37, 453, 10.1200/JCO.18.01631 Manahan, 2019, Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons, Ann Surg Oncol, 26, 3025, 10.1245/s10434-019-07549-8 Pal, 2019, Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG), Genet Med Krivokuca, 2019, Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia, J Hum Genet, 64, 281, 10.1038/s10038-019-0562-z Cragun, 2017, Care delivery considerations for widespread and equitable implementation of inherited cancer predisposition testing, Expert Rev Mol Diagn, 17, 57, 10.1080/14737159.2017.1267567 Dobričić, 2013, Serbian high-risk families: Extensive results on BRCA mutation spectra and frequency, J Hum Genet, 58, 501, 10.1038/jhg.2013.30 Krivokuca, 2015, Brankovic-Magic M. RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families, Cancer Biomarkers, 15, 775, 10.3233/CBM-150519 Greenup, 2013, Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort, Ann Surg Oncol, 20, 3254, 10.1245/s10434-013-3205-1 Müller, 2001, Quality control in mutation analysis: The European molecular Genetics Quality Network (EMQN), Eur J Pediatr, 160, 464, 10.1007/s004310100767 Pilarski R., Berry M.P., Jude S., et al. Continue NCCN Guidelines Panel Disclosures Breast surgical oncology NCCN Guidelines Version 1.2020 Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. 2019. Armstrong, 2019, A systematic review of the international prevalence of BRCA mutation in breast cancer, Clin Epidemiol, 11, 543, 10.2147/CLEP.S206949 Sokolenko, 2006, High frequency of BRCA1 5382insC mutation in Russian breast cancer patients, Eur J Cancer, 42, 1380, 10.1016/j.ejca.2006.01.050 Górski, 2004, A high proportion of founder BRCA1 mutations in Polish breast cancer families, Int J Cancer, 110, 683, 10.1002/ijc.20162 Novaković, 2012, Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families, Int J Oncol, 41, 1619, 10.3892/ijo.2012.1595 Levanat, 2012, Three novel BRCA1/BRCA2 mutations in breast/ovarian cancer families in Croatia, Gene, 498, 169, 10.1016/j.gene.2012.02.010 Antoniou, 2014, Breast-cancer risk in families with mutations in PALB2, N Engl J Med, 371, 497, 10.1056/NEJMoa1400382 Noskowicz, 2014, Prevalence of PALB2 mutation c.509-510delGA in unselected breast cancer patients from Central and Eastern Europe, Fam Cancer, 13, 137, 10.1007/s10689-013-9684-1 Jalilvand, 2017, An association study between CHEK2 gene mutations and susceptibility to breast cancer, Comp Clin Path, 26, 837, 10.1007/s00580-017-2455-x Greville-Heygate, 2020, Pathogenic variants in CHEK2 are associated with an adverse prognosis in symptomatic early-onset breast cancer, JCO Precis Oncol, 472, 10.1200/PO.19.00178 Tung, 2016, Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer, J Clin Oncol, 34, 1460, 10.1200/JCO.2015.65.0747 Hall, 2009, BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer, Cancer, 115, 2222, 10.1002/cncr.24200 Tung, 2016, Counselling framework for moderate-penetrance cancer-susceptibility mutations, Nat Rev Clin Oncol, 13, 581, 10.1038/nrclinonc.2016.90 Sung, 2020, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries., CA Cancer J Clin, 71(3), 209